Grifols Q3'26: Revenue Up 8.4% to EUR 2,040M, Net Profit Up 28% to EUR 162M, Leverage Below 4.0x
GRFS sits 22% above its 52-week low of $6.96.
Summary
Grifols grew Q3'26 revenue 8.4% at constant currency to EUR 2,040 million and net profit 28% to EUR 162 million, while net leverage fell below 4.0x to 3.98x. FY2026 guidance was confirmed and a EUR 0.15 interim dividend announced.
Key Events · Earnings and Guidance · GRFS
-
Q3'26 Revenue Grows 8.4% at Constant Currency
Revenue reached EUR 2,040 million in Q3'26, up 8.4% cc, bringing 9M'26 revenue to EUR 5,614 million (+4.6% cc), driven by Biopharma (+10.3% cc in Q3).
-
Net Profit Up 28% to EUR 162M
Q3'26 net profit rose 27.9% to EUR 162 million; 9M'26 net profit reached EUR 390 million, up 28.4%. Adjusted EBITDA margin expanded 60 bps to 26.4% in the quarter.
-
Leverage Falls Below 4.0x
Net leverage ratio declined to 3.98x from 4.2x a year earlier and 5.1x in September 2024, with liquidity of EUR 2,140 million and no significant maturities until Q4 2028.
-
China Albumin Remains the Drag
Albumin revenue fell 13.2% cc in Q3'26 and 13.9% cc year-to-date on Chinese regulatory restrictions and elevated channel inventory, partly offset by IG growth of 11.3% cc and Alpha-1 & Specialty Proteins up 18.2% cc.
Analysis · GRFS · Life Sciences
The headline is a clean quarter, but the number that matters most for the investment case is leverage: net debt to EBITDA fell to 3.98x from 4.2x a year earlier and 5.1x in September 2024, with no significant maturities until Q4 2028 and EUR 2,140 million of liquidity. Deleveraging, the overhang that has weighed on the shares, is now visibly working. Revenue of EUR 2,040 million grew 8.4% at constant currency, adjusted EBITDA margin expanded 60 basis points to 26.4%, and net profit rose 27.9% to EUR 162 million. The drag remains albumin in China, down 13.2% in the quarter on regulatory restrictions and elevated channel inventory, partly offset by immunoglobulin growth of 11.3% and Alpha-1 & Specialty Proteins up 18.2%. Full-year 2026 guidance was confirmed, and management flagged a EUR 0.15 interim dividend plus a continuing assessment of a potential US Biopharma IPO — the latter a possible re-rating event if pursued.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRFS was trading at $8.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $6.96 to $9.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.